/Investors

LifeArc Ventures

Corporate VC

London · Seed–Growth · 12 people tracked

Find your way into LifeArc Ventures

3,824 people in our graph share verified history with the LifeArc Ventures team — schools, employers, funds. One of them is your warm intro.

Ian J. Nicholsonunlockedknows Deborah Harland · together at LifeArc (overlapped)
knows the team · via Syncona Limited
×5knows the team · via Advent Life Sciences
×3knows the team · via P&G
×2knows the team · via SR One Capital Management
✨ Fox Verdict
Sign up to see your fit

Investment thesis

LifeArc Ventures invests from Seed to Series B in therapeutics and medtech companies across all therapeutic areas and a diverse range of modalities, co-investing alongside other leading life sciences venture funds globally. As part of LifeArc, a self-funded medical research organisation, it offers portfolio companies a combination of scientific, commercial and financial support, drawing on access to leading scientists with deep translational science expertise. The team blends financial, operational and scientific experience spanning venture capital, investment banking, pharma and biotech business development, and clinical practice. It seeks companies with the potential to deliver meaningful patient impact while generating returns that LifeArc can reinvest in its core objectives.

Source: firm website, verified Aug 7, 2026.

Stage
Seed–Growth
HQ
London, GB
Leads rounds
Leads
Instruments
Equity
Last 12 months
2 investments
Tracked investments
23

Team · 12 people

from the firm's website

Founder mafia

2 people who came through LifeArc Ventures went on to found or lead other companies.

What they invest in

from 20 of 23 portfolio companies

Biotech ×18Healthtech ×14Digital Health ×6Medical Devices ×5Deep Tech ×4AI & Machine Learning ×2Longevity ×2Advanced Manufacturing ×1

HQs:United Kingdom×6Germany×2United States×2Belgium×1Canada×1

Who they back

founder profiles across 11 portfolio companies
45%
solo founders
5 of 11 mapped founding teams
33%
repeat founders
of 12 founders with career history

Founding team size:solo founder×52 founders×43 founders×2

Where their founders studiedfrom 10 founders with education data

University of Aberdeen ×2

What their founders studiedfrom 10 founders with field-of-study data

Life Sciences ×4Medicine ×3

Where their founders worked beforefrom 12 founders with career history

King's College London ×2

Investments · 23 tracked

founders shown can be your intro path

By year:2026 · 22025 · 22024 · 12023 · 16 dated

Ikarovec Seedikarovec.comin✓ verified

Ikarovec is a biotech company focused on developing treatments for retinal diseases affecting vision.

BiotechDeep TechDigital HealthHealthtechMedical DevicesNorwich, GB

Peter Widdowson, PhD(Scientific Founder)Thomas Ciulla, M.D, MBA(President and Chief Executive Officer)in

Co-investorsFuture Planet CapitalUK Innovation & Science Seed Fund

Maxion Therapeutics Websitemaxiontherapeutics.comin𝕏✓ verified

Maxion Therapeutics develops protein and antibody therapeutics using its patented KnotBody technology, which fuses cysteine-rich miniproteins (Knottins) into antibody binding loops to target ion channels and GPCRs.

BiotechHealthtechCambridge, GB

John McCafferty(Co-founder and CTO)inAneesh Karatt-Vellatt(Co-founder and CSO)in

Co-investorsMonograph Capital PartnersGeneral CatalystSolasta Ventures

Affect Therapeuticsaffecttherapeutics.comin𝕏Jul 2023 · $16M

Affect Therapeutics operates an app-based digital treatment provider offering care for substance use disorders (alcohol, cannabis, opioid) and mental health conditions like depression and anxiety, using methods such as contingency management, CBT, medication-assisted treatment, and peer support.

Digital HealthHealthtechMental HealthNew York, US

Jeff DeFlavio(Co-founder)inKristin Muhlner(Executive Officer, Director)in

BoardKevin Ryan(Director)inJeff Rinehart(Director)in

Co-investorsArtis VenturesCity LightAlleyCorpKapor CapitalSamsung NextWhat If Ventures+1 more

AviadoBio Websiteaviadobio.comin𝕏

AviadoBio is a gene therapy company developing adeno-associated viral (AAV) treatments for neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

BiotechDeep TechDigital HealthHealthtech

Chris Shaw(Co-Founder & Chief Scientific and Clinical Advisor)inDo Young Lee(Co-Founder)Youn Bok Lee(Co-Founder)inLisa Deschamps(Chief Executive Officer)inGraeme Fielder(Chief Operating Officer)inAlex Bloom(Chief Development Officer)in

Co-investorsAdvent Life SciencesDementia DiscoveryF-Prime CapitalMonograph Capital PartnersNew Enterprise Associates (NEA)

Climb Bio Websiteclimbbio.comin𝕏

Climb Bio develops monoclonal antibody therapies for immune-mediated diseases, advancing clinical-stage candidates such as budoprutug for conditions including immune thrombocytopenia.

BiotechHealthtech

Aoife Brennan, MB, ChB(President and Chief Executive Officer)Perrin Wilson, PhD(Chief Business Officer)Susan Altschuller, PhD, MBA(Chief Financial Officer)Edgar Charles, MD(Chief Medical Officer)Ashley Jones(Senior Vice President, People & Workforce Strategy)inAdam Villa, MBA, MS(Senior Vice President, Technical Operations)

Corteriapharmacorteriapharma.comin

Corteria Pharma develops interceptive therapies aimed at treating subpopulations of patients with heart failure, sarcopenia, and obesity.

BiotechDigital HealthHealthtechLongevity

Philip JaniakinMarie-Laure OzouxinRégis OlivierinFrancesca C. LawsonMark KowalaEleonore Jouannyin

Co-investorsFountain Healthcare PartnersJeito CapitalKurma PartnersOrbiMedV-Bio VenturesOmnes Capital+1 more

cumulus-neurosciencecumulusneuro.comin

NeuLogiq is a research platform for clinical trials that integrates tablet-based cognitive assessments, EEG monitoring, and real-world behavioral data to measure brain function changes.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesBelfast, GB

Brian Murphy(Co-Founder & CSO)inTina(CEO)

Co-investorsDementia Discovery FundClarendon Fund Managers Ltd.

Cytospire Therapeutics Websitecytospire.com

Cytospire Therapeutics develops multispecific antibodies and next-generation γδ T cell engagers designed to direct innate and adaptive immune effector cells as an alternative to CD3-based engagers.

BiotechHealthtech

Co-investorsCriteria Bio VenturesMedical Incubator Japan K.K.Modi VenturesPathway BioventuresSound Bioventures

Droia Venturesdroiaventures.cominJan 2026

Droia Ventures is a specialist venture capital firm investing globally in early-stage drug development companies focused on therapeutics for oncology and genetic disease.

BiotechLeuven, BE

Co-investorsClavystBioFrazier Life SciencesNovo Holdings

Exciva Websiteexciva.com

Exciva is a company focused on neurological and neurodegenerative conditions, led by a team with expertise in chemistry, clinical operations, and regulatory affairs.

BiotechDigital HealthLongevityMedical DevicesHeidelberg, DE

Hans Moebius(Co-founder and CMO, Head of Clinical Operations)inAnton Bespalov(Co-founder and CSO, Head of Regulatory Affairs)in

Co-investorsAndera PartnersFountain Healthcare PartnersModi Ventures

Extracellularextracellular.cominMay 2025 · $130M

Extracellular is a biomanufacturing company that helps cell-based product developers in cultivated meat, plant cell culture, and bioactives accelerate discovery, overcome production challenges, and commercialize their products.

Advanced ManufacturingBiotechFoodTechNew Materials

Will Milligan(CEO & Founder)in

Co-investorsBig Idea VenturesFFFNewland SyndicateUnruly Capital5AM VenturesAgent Capital+8 more

Fluid Biomedfluidbiomed.comDec 2024 · $27M

Fluid Biomed develops a bioresorbable polymer-based stent designed to treat brain aneurysms by diverting blood flow and reducing risk of stroke.

BiotechDeep TechHealthtechMedical DevicesCalgary, CA

Dr. John H. Wong(Co-founder & Chief Executive Officer)Dr. Alim P. Mitha(Co-founder, President & Chief Technology Officer)

Co-investorsAccelerate FundShangBay Capital LLCThin Air LabsUCeed FundsAmplitude Venture CapitalIAG Capital Partners

GlycoEraglycoera.comin𝕏

GlycoEra develops glycan-based therapeutics, applying glycoengineering technology to create biologic drugs.

BiotechHealthtechNewton, US

Ganesh V. Kaundinya(President & CEO)in

Co-investors5AM VenturesCatalio Capital Management, LPRoche Venture FundSixty Degree CapitalSofinnova PartnersAgent Capital+1 more

HillStar Bio Websitehillstarbio.comin

Hillstar Bio develops precision immunotherapies for autoimmune diseases, using antibody engineering to selectively deplete pathogenic immune cells while sparing healthy ones.

BiotechHealthtech

Co-investorsDroia VenturesFrazier Life Sciences

MC Sciences Websitemcsciences.comin

MC Sciences is a biotech company developing first-in-class mast cell therapeutics based on a discovered mast cell receptor, aimed at diseases across immunology, dermatology, respiratory, gastrointestinal, fibrotic and chronic inflammatory conditions such as chronic urticaria, systemic mastocytosis, COPD, asthma and MCAS.

BiotechHealthtech

Gerhard J. Molderings(Founder)Wolfgang Taumann(CEO & Co-Founder)in

BoardMikael Dolsten(Board Chairman)

Co-investorsROC Venture Group

Ozlo Sleepozlosleep.comin𝕏

Ozlo manufactures sleep wellness products including blackout sleep masks and audio devices designed to improve sleep quality through light and sound control.

ConsumerHardwareWellness & Fitness

Co-investorsArtis Ventures

Pheno Therapeutics Websitephenotherapeutics.comin

Pheno Therapeutics is a clinical-stage biotech company developing GPR17 antagonists that target oligodendrocytes to promote brain repair.

BiotechMedical DevicesEdinburgh, GB

Neil Carragher(Founder)in

Co-investorsAdvent Life Sciences

RQ Biorqbiotechnology.comJun 2026 · $115M

RQ Bio discovers and develops long-acting monoclonal antibodies (LAAbs) targeting seasonal influenza to provide protection against severe viral disease.

BiotechHealthtech

Co-investorsFrazier Life SciencesEQT Life SciencesForbionOxford Science EnterprisesRed Tree VentureWellington Management

T-Cypher Biotcypherbio.comin

T-Cypher Bio develops drugs with curative potential, focusing on antibody development, T cell biology, and TCR discovery.

AI & Machine LearningBiotechDeep Tech

Co-investorsFuture Planet CapitalOxford Science EnterprisesPerivoli Innovations

Tribune Therapeutics ABtribunetx.cominMar 2025

Tribune Therapeutics is a preclinical biopharmaceutical company developing medicines that target CCN protein family signaling (such as CCN2/CTGF) to block fibrotic pathways.

BiotechHealthtech

Ole Kaasbøll(Co-founder)

Co-investorsHealthCapIndustrifondenInnovestor VenturesInvestinorNovo Holdings

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Hillstar BioMaxion TherapeuticsPheno Therapeutics

Portfolio news

latest coverage across their companies

Frequently asked questions

How many investments has LifeArc Ventures made?
LifeArc Ventures has 23 tracked investments, including 5 dated in the last 24 months.
What stage does LifeArc Ventures invest at?
LifeArc Ventures invests at the Seed, Series A, Series B, Series C, Growth stages.
What sectors does LifeArc Ventures focus on?
LifeArc Ventures focuses on Biotech, Digital Health, Healthtech, IoT, Medical Devices.
Where is LifeArc Ventures located?
LifeArc Ventures is headquartered in London, GB.
Does LifeArc Ventures lead rounds?
Yes, LifeArc Ventures leads investment rounds.
Who does LifeArc Ventures co-invest with?
LifeArc Ventures most often shares deals with Advent Life Sciences, Monograph Capital Partners, Artis Ventures, among 42 tracked co-investors.

Similar investors

Featured in lists